- Utilise conformation-specific monoclonal antibodies to ensure accurate dp-ucMGP circulating levels
- Correlated to the widely published lab-develop dp-ucMGP ELISA assay method
- Wide assay range suitable for Chronic Kidney Disease, Haemodialysis and Vitamin K Antagonist treated patients
- First fully automated CE marked IVD dp-ucMGP test for achieving fast and highly reproducible results for diagnostic and follow up of patients
An automated assay for the quantitative determination of the inactive dephosphorylated-uncarboxylated (dp-uc) isoform of Matrix Gla-Protein (MGP) in human plasma on the IDS-iSYS Multi-Discipline Automated System. Measurement of dp-ucMGP are used in the assessment of vitamin K status in the arterial vessel wall.
Matrix Gla-Protein (MGP) is the most potent inhibitor of tissue calcification presently known. MGP is a ɣ-carboxylated 11 kDa protein, comprised of 84 amino acids, which is mainly expressed and secreted by chondrocytes and vascular smooth muscle cells in the arterial media.1 Vitamin K serves as a co-factor for the enzyme ɣ-glutamate carboxylase that converts glutamate residues into ɣ-carboxyglutamate (Gla). These Gla-residues serve as calcium-binding groups, which are essential for the activity of all Gla-containing proteins including MGP. Besides carboxylation, MGP also undergoes post-translational serine phosphorylation during maturation. Whereas carboxylation is essential for its calcification inhibitory activity, its cellular secretion is enhanced by phosphorylation.2,3 At least four different MGP species are formed with varying states of phosphorylation and/or carboxylation: phosphorylated carboxylated MGP (p-cGMP), phosphorylated uncarboxylated MGP (p-ucMGP), desphospho-carboxylated MGP (dp-cMGP), and desphospho-uncarboxylated MGP (dp-ucMGP). Circulating forms of MGP have no known biological function, but reflect the extent of vascular calcification and availability of Vitamin K in the vessel wall.2,4,5
(1) Price PA, Urist MR, Otawara Y: Matrix Gla protein, a new gammacarboxyglutamic acid-containing protein which is associated with the organic matrix of bone. Biochem Biophys Res Commun 1983, 117:765–771.
(2) Cranenburg EC, Koos R, Schurgers LJ, Magdeleyns EJ, Schoonbrood TH, Landewé RB et al. Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. Thromb Haemost. 2010; 104: 811–822.
(3) Schurgers LJ, Spronk HM, Skepper JN, Hackeng TM, Shanahan CM, Vermeer C et al. Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification. J Thromb Haemost. 2007; 5: 2503–2511.
(4) Murshed M, Schinke T, McKee MD et al. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 2004; 165:625-630.
(5) Schurgers LJ, Cranenburg EC, Vermeer C. Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Thromb Haemost. 2008; 100: 593–603.
* Available in selected markets, product availability subject to required regulatory approval
NB: Ostase® is a registered trademark of Hybritech Incorporated, a subsidiary of Beckman Coulter, Inc.